| Literature DB >> 33807959 |
Ana Rita de Oliveira Dos Santos1, Bárbara de Oliveira Zanuso1, Vitor Fernando Bordin Miola1, Sandra Maria Barbalho1,2,3, Patrícia C Santos Bueno1,4, Uri Adrian Prync Flato1,2, Claudia Rucco P Detregiachi2, Daniela Vieira Buchaim1,2,5, Rogério Leone Buchaim6, Ricardo José Tofano1,2, Claudemir Gregório Mendes1,2, Viviane Alessandra Capelluppi Tofano1, Jesselina F Dos Santos Haber1.
Abstract
Adipose, skeletal, and hepatic muscle tissues are the main endocrine organs that produce adipokines, myokines, and hepatokines. These biomarkers can be harmful or beneficial to an organism and still perform crosstalk, acting through the endocrine, paracrine, and autocrine pathways. This study aims to review the crosstalk between adipokines, myokines, and hepatokines. Far beyond understanding the actions of each biomarker alone, it is important to underline that these cytokines act together in the body, resulting in a complex network of actions in different tissues, which may have beneficial or non-beneficial effects on the genesis of various physiological disorders and their respective outcomes, such as type 2 diabetes mellitus (DM2), obesity, metabolic syndrome, and cardiovascular diseases (CVD). Overweight individuals secrete more pro-inflammatory adipokines than those of a healthy weight, leading to an impaired immune response and greater susceptibility to inflammatory and infectious diseases. Myostatin is elevated in pro-inflammatory environments, sharing space with pro-inflammatory organokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), resistin, and chemerin. Fibroblast growth factor FGF21 acts as a beta-oxidation regulator and decreases lipogenesis in the liver. The crosstalk mentioned above can interfere with homeostatic disorders and can play a role as a potential therapeutic target that can assist in the methods of diagnosing metabolic syndrome and CVD.Entities:
Keywords: adipokines; cardiovascular diseases; hepatokines; metabolism; myokines
Mesh:
Substances:
Year: 2021 PMID: 33807959 PMCID: PMC7961600 DOI: 10.3390/ijms22052639
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923